4.5 Review

The current status, challenges, and future developments of new tuberculosis vaccines

Journal

HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 14, Issue 7, Pages 1697-1716

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2018.1458806

Keywords

BCG; Clinical trials; Immunology; Mycobacterium tuberculosis; Tuberculosis; Vaccines

Funding

  1. Serious Infectious Diseases Special Foundation of China [2012ZX10003008002]
  2. WHO IVR Steering Committee [V25-181-202]
  3. National Nature and Science Foundation of China [30070730]
  4. Medical Science and Technology Youth Cultivation Program of PLA [16QNP075]
  5. Outstanding Talent Training Project of Beijing [2016000057592G265]
  6. Key Subject Foundation of the 309th Hospital of Chinese PLA [2016-ZD-001]

Ask authors/readers for more resources

Mycobacterium tuberculosis complex causes tuberculosis (TB), one of the top 10 causes of death worldwide. TB results in more fatalities than multi-drug resistant (MDR) HIV strain related coinfection. Vaccines play a key role in the prevention and control of infectious diseases. Unfortunately, the only licensed preventive vaccine against TB, bacilli Calmette-Guerin (BCG), is ineffective for prevention of pulmonary TB in adults. Therefore, it is very important to develop novel vaccines for TB prevention and control. This literature review provides an overview of the innate and adaptive immune response during M. tuberculosis infection, and presents current developments and challenges to novel TB vaccines. A comprehensive understanding of vaccines in preclinical and clinical studies provides extensive insight for the development of safer and more efficient vaccines, and may inspire new ideas for TB prevention and treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available